Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Induced Pluripotent Stem Cells | 6 | 2018 | 584 | 2.03 | Why? |
| Ventricular Remodeling | 3 | 2021 | 349 | 1.08 | Why? |
| Myocytes, Cardiac | 4 | 2021 | 804 | 0.78 | Why? |
| Channelopathies | 1 | 2018 | 12 | 0.75 | Why? |
| Neprilysin | 1 | 2019 | 112 | 0.73 | Why? |
| Sarcomeres | 1 | 2017 | 7 | 0.71 | Why? |
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2017 | 16 | 0.70 | Why? |
| Electrophysiological Phenomena | 1 | 2017 | 59 | 0.69 | Why? |
| Cardiotoxins | 1 | 2017 | 22 | 0.68 | Why? |
| Heart Failure, Systolic | 1 | 2017 | 39 | 0.67 | Why? |
| Kruppel-Like Transcription Factors | 1 | 2017 | 91 | 0.65 | Why? |
| Drugs, Investigational | 1 | 2019 | 198 | 0.64 | Why? |
| Cell Differentiation | 3 | 2018 | 1338 | 0.57 | Why? |
| Genetic Therapy | 1 | 2017 | 409 | 0.48 | Why? |
| Long QT Syndrome | 2 | 2018 | 1047 | 0.45 | Why? |
| Ventricular Function, Left | 2 | 2017 | 1555 | 0.45 | Why? |
| RNA | 1 | 2017 | 1278 | 0.40 | Why? |
| Sotalol | 2 | 2018 | 9 | 0.37 | Why? |
| Myocardium | 2 | 2017 | 2323 | 0.36 | Why? |
| Myocardial Infarction | 3 | 2019 | 3361 | 0.34 | Why? |
| Antihypertensive Agents | 1 | 2019 | 1962 | 0.33 | Why? |
| Arrhythmias, Cardiac | 2 | 2018 | 2510 | 0.32 | Why? |
| Pharmacogenetics | 2 | 2017 | 222 | 0.28 | Why? |
| AIDS-Associated Nephropathy | 1 | 2003 | 18 | 0.27 | Why? |
| Cardiovascular Diseases | 4 | 2020 | 11497 | 0.27 | Why? |
| Anti-Arrhythmia Agents | 2 | 2017 | 325 | 0.27 | Why? |
| Adipose Tissue | 2 | 2017 | 612 | 0.22 | Why? |
| Heart | 3 | 2021 | 1791 | 0.22 | Why? |
| Coronary Artery Disease | 3 | 2021 | 2570 | 0.21 | Why? |
| Angina, Stable | 1 | 2019 | 45 | 0.20 | Why? |
| Pancreatitis-Associated Proteins | 1 | 2018 | 5 | 0.19 | Why? |
| Lipodystrophy, Familial Partial | 1 | 2018 | 1 | 0.19 | Why? |
| Fetal Proteins | 1 | 2018 | 5 | 0.19 | Why? |
| Polycomb-Group Proteins | 1 | 2018 | 8 | 0.19 | Why? |
| Lamin Type A | 1 | 2018 | 14 | 0.19 | Why? |
| Androstenes | 1 | 2018 | 65 | 0.19 | Why? |
| Hypertension | 2 | 2021 | 8895 | 0.18 | Why? |
| Heart Ventricles | 2 | 2017 | 1139 | 0.18 | Why? |
| T-Box Domain Proteins | 1 | 2018 | 62 | 0.18 | Why? |
| Morphine | 1 | 2018 | 71 | 0.18 | Why? |
| Valsartan | 1 | 2019 | 206 | 0.18 | Why? |
| Biphenyl Compounds | 1 | 2019 | 249 | 0.18 | Why? |
| Transcription Activator-Like Effector Nucleases | 1 | 2017 | 4 | 0.18 | Why? |
| Cell Tracking | 1 | 2017 | 10 | 0.18 | Why? |
| Aminobutyrates | 1 | 2019 | 142 | 0.18 | Why? |
| Obesity | 4 | 2021 | 7388 | 0.18 | Why? |
| Adipocytes, Beige | 1 | 2017 | 2 | 0.18 | Why? |
| Potassium Channels | 1 | 2017 | 33 | 0.18 | Why? |
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2017 | 10 | 0.17 | Why? |
| Thermogenesis | 1 | 2017 | 14 | 0.17 | Why? |
| Infusions, Intra-Arterial | 1 | 2017 | 36 | 0.17 | Why? |
| Gene Expression Regulation, Developmental | 1 | 2018 | 159 | 0.17 | Why? |
| Myocardial Revascularization | 1 | 2019 | 267 | 0.17 | Why? |
| Cellular Reprogramming Techniques | 1 | 2017 | 43 | 0.16 | Why? |
| Vascular Calcification | 1 | 2021 | 396 | 0.16 | Why? |
| Tetrazoles | 1 | 2019 | 262 | 0.16 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.16 | Why? |
| Gene Library | 1 | 2017 | 234 | 0.16 | Why? |
| Microscopy, Fluorescence | 1 | 2017 | 335 | 0.16 | Why? |
| Fibroblasts | 2 | 2018 | 839 | 0.16 | Why? |
| Cytochrome P-450 CYP2C19 | 1 | 2015 | 25 | 0.15 | Why? |
| Amiodarone | 1 | 2017 | 110 | 0.15 | Why? |
| Adipocytes | 1 | 2017 | 173 | 0.15 | Why? |
| Tachycardia | 1 | 2017 | 239 | 0.15 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 1 | 2021 | 520 | 0.15 | Why? |
| Action Potentials | 1 | 2017 | 368 | 0.15 | Why? |
| Platelet Aggregation Inhibitors | 2 | 2017 | 1671 | 0.15 | Why? |
| Purinergic P2Y Receptor Antagonists | 1 | 2017 | 206 | 0.15 | Why? |
| beta-Alanine | 1 | 2014 | 20 | 0.14 | Why? |
| Gonadal Steroid Hormones | 1 | 2017 | 328 | 0.14 | Why? |
| Gene Editing | 1 | 2018 | 330 | 0.14 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2018 | 3607 | 0.14 | Why? |
| Insulin Resistance | 2 | 2017 | 669 | 0.14 | Why? |
| Pain, Postoperative | 1 | 2018 | 289 | 0.14 | Why? |
| Heart Atria | 1 | 2017 | 267 | 0.14 | Why? |
| Research Subjects | 1 | 2017 | 178 | 0.14 | Why? |
| Androgen Antagonists | 1 | 2018 | 404 | 0.14 | Why? |
| Thiophenes | 1 | 2014 | 78 | 0.13 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2021 | 5277 | 0.13 | Why? |
| Acute Coronary Syndrome | 2 | 2018 | 2107 | 0.13 | Why? |
| Cell Culture Techniques | 1 | 2017 | 704 | 0.12 | Why? |
| Glucose | 1 | 2017 | 573 | 0.12 | Why? |
| Morpholines | 1 | 2014 | 351 | 0.12 | Why? |
| Mice, Inbred C57BL | 3 | 2018 | 5542 | 0.12 | Why? |
| Hemodynamics | 2 | 2018 | 1562 | 0.12 | Why? |
| Benzimidazoles | 1 | 2014 | 275 | 0.11 | Why? |
| Shock, Cardiogenic | 1 | 2018 | 700 | 0.11 | Why? |
| Endothelial Cells | 2 | 2020 | 2048 | 0.11 | Why? |
| Stem Cells | 1 | 2017 | 595 | 0.11 | Why? |
| Antithrombins | 1 | 2014 | 353 | 0.11 | Why? |
| Chromatography, High Pressure Liquid | 1 | 2014 | 669 | 0.10 | Why? |
| Genome-Wide Association Study | 1 | 2017 | 1648 | 0.10 | Why? |
| Schools, Medical | 1 | 2017 | 793 | 0.10 | Why? |
| Drug Approval | 1 | 2019 | 1325 | 0.10 | Why? |
| Drug Delivery Systems | 1 | 2019 | 1365 | 0.10 | Why? |
| Coronary Vessels | 1 | 2017 | 914 | 0.10 | Why? |
| Drug Combinations | 1 | 2019 | 3852 | 0.10 | Why? |
| Factor Xa Inhibitors | 1 | 2014 | 490 | 0.10 | Why? |
| Kidney | 1 | 2003 | 3648 | 0.10 | Why? |
| Flow Cytometry | 1 | 2017 | 2393 | 0.09 | Why? |
| Gene Expression Profiling | 2 | 2017 | 3788 | 0.09 | Why? |
| Tandem Mass Spectrometry | 1 | 2014 | 1031 | 0.09 | Why? |
| Analgesics, Opioid | 1 | 2018 | 1070 | 0.09 | Why? |
| Humans | 33 | 2021 | 930598 | 0.09 | Why? |
| Prospective Studies | 10 | 2021 | 43301 | 0.09 | Why? |
| Heart Rate | 1 | 2017 | 1527 | 0.09 | Why? |
| Adipogenesis | 2 | 2017 | 38 | 0.09 | Why? |
| Stroke Volume | 1 | 2017 | 2153 | 0.08 | Why? |
| Echocardiography | 2 | 2018 | 3661 | 0.08 | Why? |
| Liver | 1 | 2021 | 4007 | 0.08 | Why? |
| Drug Monitoring | 1 | 2014 | 1408 | 0.08 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.08 | Why? |
| Double-Blind Method | 1 | 2017 | 5988 | 0.07 | Why? |
| Coronary Angiography | 3 | 2021 | 2275 | 0.07 | Why? |
| Fibrosis | 2 | 2021 | 800 | 0.07 | Why? |
| Renin-Angiotensin System | 1 | 2021 | 3661 | 0.07 | Why? |
| Paris | 2 | 2020 | 1287 | 0.07 | Why? |
| Female | 20 | 2021 | 380317 | 0.07 | Why? |
| Ticlopidine | 2 | 2017 | 193 | 0.07 | Why? |
| Forecasting | 1 | 2019 | 4492 | 0.07 | Why? |
| Male | 19 | 2021 | 367725 | 0.07 | Why? |
| Patient Safety | 1 | 2019 | 4885 | 0.07 | Why? |
| Heart Diseases | 1 | 2021 | 3503 | 0.07 | Why? |
| Mice | 3 | 2018 | 21357 | 0.06 | Why? |
| Cohort Studies | 7 | 2021 | 36005 | 0.06 | Why? |
| Middle Aged | 15 | 2021 | 270681 | 0.06 | Why? |
| Anticoagulants | 2 | 2020 | 9563 | 0.06 | Why? |
| Percutaneous Coronary Intervention | 1 | 2018 | 3646 | 0.05 | Why? |
| Norpregnenes | 1 | 2018 | 5 | 0.05 | Why? |
| Aged | 10 | 2021 | 215776 | 0.05 | Why? |
| Models, Biological | 1 | 2017 | 4907 | 0.05 | Why? |
| Desogestrel | 1 | 2018 | 10 | 0.05 | Why? |
| Levonorgestrel | 1 | 2018 | 12 | 0.05 | Why? |
| Precision Medicine | 2 | 2021 | 1477 | 0.05 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.05 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2018 | 5002 | 0.05 | Why? |
| Mesoderm | 1 | 2018 | 15 | 0.05 | Why? |
| Catechol O-Methyltransferase | 1 | 2018 | 25 | 0.05 | Why? |
| Contraceptive Agents, Female | 1 | 2018 | 41 | 0.05 | Why? |
| Receptors, Opioid, mu | 1 | 2018 | 23 | 0.05 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.05 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.05 | Why? |
| Recurrence | 2 | 2019 | 3675 | 0.04 | Why? |
| Animals | 5 | 2021 | 78931 | 0.04 | Why? |
| Isoproterenol | 1 | 2017 | 31 | 0.04 | Why? |
| Epididymis | 1 | 2017 | 23 | 0.04 | Why? |
| Platelet-Derived Growth Factor | 1 | 2017 | 21 | 0.04 | Why? |
| Cell Transplantation | 1 | 2017 | 21 | 0.04 | Why? |
| Blood Coagulation | 2 | 2021 | 2768 | 0.04 | Why? |
| Body Mass Index | 2 | 2021 | 4306 | 0.04 | Why? |
| Intra-Aortic Balloon Pumping | 1 | 2018 | 125 | 0.04 | Why? |
| Adipose Tissue, White | 1 | 2017 | 30 | 0.04 | Why? |
| Adult | 12 | 2021 | 244371 | 0.04 | Why? |
| Adrenergic beta-Agonists | 1 | 2017 | 93 | 0.04 | Why? |
| Biomarkers | 4 | 2021 | 23361 | 0.04 | Why? |
| Cell Lineage | 1 | 2018 | 241 | 0.04 | Why? |
| Systole | 1 | 2017 | 252 | 0.04 | Why? |
| Follow-Up Studies | 3 | 2021 | 17020 | 0.04 | Why? |
| Treatment Outcome | 3 | 2019 | 51732 | 0.04 | Why? |
| Prasugrel Hydrochloride | 1 | 2017 | 114 | 0.04 | Why? |
| Primary Cell Culture | 1 | 2018 | 501 | 0.04 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.04 | Why? |
| Lung | 2 | 2021 | 31049 | 0.04 | Why? |
| Platelet Aggregation | 1 | 2017 | 318 | 0.04 | Why? |
| Genome | 1 | 2017 | 341 | 0.04 | Why? |
| Principal Component Analysis | 1 | 2017 | 689 | 0.04 | Why? |
| Chemokines | 1 | 2021 | 1095 | 0.04 | Why? |
| France | 2 | 2021 | 12074 | 0.03 | Why? |
| Drug Stability | 1 | 2014 | 236 | 0.03 | Why? |
| Hemostasis | 1 | 2020 | 811 | 0.03 | Why? |
| Calibration | 1 | 2014 | 307 | 0.03 | Why? |
| Electrocardiography | 2 | 2018 | 3957 | 0.03 | Why? |
| Risk Factors | 5 | 2021 | 71621 | 0.03 | Why? |
| Adenosine | 1 | 2017 | 509 | 0.03 | Why? |
| Homeostasis | 1 | 2017 | 582 | 0.03 | Why? |
| Cold Temperature | 1 | 2014 | 260 | 0.03 | Why? |
| Gene Regulatory Networks | 1 | 2018 | 820 | 0.03 | Why? |
| Dabigatran | 1 | 2014 | 204 | 0.03 | Why? |
| Propensity Score | 1 | 2021 | 2690 | 0.03 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.03 | Why? |
| Oxygen Consumption | 1 | 2017 | 711 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.03 | Why? |
| Radiopharmaceuticals | 1 | 2017 | 763 | 0.03 | Why? |
| Alleles | 1 | 2017 | 1557 | 0.03 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.03 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.03 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
| Tomography, X-Ray Computed | 3 | 2021 | 25144 | 0.03 | Why? |
| Body Weight | 1 | 2017 | 1074 | 0.03 | Why? |
| Signal Transduction | 2 | 2018 | 7207 | 0.03 | Why? |
| Rivaroxaban | 1 | 2014 | 467 | 0.03 | Why? |
| Demography | 1 | 2017 | 1660 | 0.03 | Why? |
| Reference Standards | 1 | 2014 | 1163 | 0.03 | Why? |
| Inflammation Mediators | 1 | 2021 | 2654 | 0.02 | Why? |
| Mitochondria | 1 | 2017 | 857 | 0.02 | Why? |
| Endothelium, Vascular | 1 | 2021 | 1751 | 0.02 | Why? |
| Pain Management | 1 | 2018 | 854 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.02 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2017 | 1153 | 0.02 | Why? |
| Molecular Structure | 1 | 2014 | 1539 | 0.02 | Why? |
| Reproducibility of Results | 2 | 2017 | 11304 | 0.02 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.02 | Why? |
| Aspirin | 1 | 2017 | 1043 | 0.02 | Why? |
| Up-Regulation | 1 | 2017 | 2249 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Transcriptome | 1 | 2021 | 3466 | 0.02 | Why? |
| Linear Models | 1 | 2014 | 1914 | 0.02 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.02 | Why? |
| Recovery of Function | 1 | 2018 | 2461 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2019 | 6543 | 0.02 | Why? |
| Blood Coagulation Disorders | 1 | 2020 | 2040 | 0.02 | Why? |
| Limit of Detection | 1 | 2014 | 2698 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Smoking | 1 | 2019 | 3358 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2021 | 9537 | 0.02 | Why? |
| Blood Platelets | 1 | 2017 | 1704 | 0.02 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.02 | Why? |
| Genomics | 1 | 2017 | 3118 | 0.02 | Why? |
| Prognosis | 2 | 2019 | 32490 | 0.02 | Why? |
| Anti-HIV Agents | 1 | 2017 | 2209 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.02 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.02 | Why? |
| Young Adult | 3 | 2020 | 93724 | 0.02 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.02 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.02 | Why? |
| Genotype | 1 | 2015 | 4697 | 0.02 | Why? |
| Time Factors | 2 | 2018 | 31397 | 0.02 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.02 | Why? |
| Europe | 1 | 2018 | 12702 | 0.01 | Why? |
| Protein Binding | 1 | 2018 | 11430 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.01 | Why? |
| Registries | 1 | 2019 | 12327 | 0.01 | Why? |
| Antiviral Agents | 2 | 2021 | 41703 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Adolescent | 2 | 2020 | 86841 | 0.01 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.01 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 11367 | 0.01 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.01 | Why? |
| Stroke | 1 | 2019 | 8839 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Pandemics | 2 | 2021 | 389249 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Critical Illness | 1 | 2017 | 17281 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |
Hulot's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(251)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(131)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_